Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $1,550.0 million
Deal Type : Divestment
Details : The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUP...
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : $1,100.0 million
July 13, 2022
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $1,550.0 million
Deal Type : Divestment
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gsk Launches Once Daily, Single Inhaler-Triple Therapy for COPD Patients for the First Time in India
Details : Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is approved in combination with umeclidinium & vilanterol for the treatment of chronic obstructive pulmonary disease.
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gsk Confirms Therapeutic Efficacy of COPD Triple-Therapy Inhaler
Details : Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is being evaluated in phase 4 clinical trials in combination with umeclidinium & vilanterol for the treatment of chronic obstructive pulmonary disease.
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Opinions: EMA Refuses Asthma Label Expansion for GSK’s Copd Drug Trelegy Ellipta
Details : The European Union’s healthcare regulator the European Medicines Agency (EMA) has decided against a label expansion for GlaxoSmithKline (GSK)’s drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include asthma.
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with COPD.
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : Inapplicable
September 09, 2020
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is under phase 3 clinical development in combination with umeclidinium & vilanterol for the treatment of adult patients with Asthma.
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable